🇺🇸 FDA
Patent

US 10316318

Oligonucleotide compositions and uses thereof

granted A61PA61P35/00A61P35/02

Quick answer

US patent 10316318 (Oligonucleotide compositions and uses thereof) held by MIRAGEN THERAPEUTICS, INC. expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
MIRAGEN THERAPEUTICS, INC.
Grant date
Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P35/00, A61P35/02, A61P43/00